Clinical Trial Indicates Improvement in Survival Rate of Lung Cancer Patients

Your ads will be inserted here byEasy Plugin for AdSense.Please go to the plugin admin page toPaste your ad code OR Suppress this ad slot. Modulation of the immune system of a lung cancer patient for acting against the lung cancer cells has not been successful in the past. But advances in the understanding of the immune response to tumors helped development of antigens that yielded promising results in various clinical studies. Squamous non-small cell lung cancer or NSCLC is responsible for 25 to 30% of all lung malignancies. In a comparative clinical trial conducted researchers found that the patients who were treated with nivolumab the immunotherapy drug had, on an average, a life span 3.2 months more than those treated with chemotherapy. Results of the trial, published in the New England Journal of Medicine and presented at the 2015 American Society for Clinical Oncology (ASCO) Annual Meeting, also showed that after one year patients having nivolumab had a survival rate of 42% a
http://cancerinlungs.com/clinical-trial-indicates-improvement-in-survival-rate-of-lung-cancer-patients/